NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...
Smith, a microbiologist whose discovery revolutionize the field of genetic engineering, was a Johns Hopkins School of Medicine alumnus and professor emeritus ...
The grantmaking organization Open Philanthropy has awarded funding for a University of California San Diego technology ...
Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...
In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...
First company to enable precision in vivo genome engineering, combining both cell-specific delivery and programmable, locus-specific gene insertion, with the potential to achieve physiological, ...
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...
According to Nova One Advisor, the global gene editing market size is calculated at USD 11.29 billion in 2025 and is expected ...
Researchers have gained new insights into the genetic basis of rye reproduction. They have demonstrated how plants recombine ...
Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by chemist Brian Liau and his collaborators at Harvard offers an ...
Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.
The surge in genetic disorders such as cystic fibrosis ... Nikhil holds an MBA degree in Marketing and IT and a Graduate in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback